About Us
DuoCort in Brief
|
DuoCort has developed Plenadren, a once daily dual-release hydrocortisone replacement therapy for patients with chronic adrenal insufficiency. Plenadren has orphan status in Europe and the USA and is currently in the European Union (EU) registration process for marketing authorisation.
As of November 15, 2011, DuoCort is a wholly-owned subsidiary of ViroPharma. To learn more about ViroPharma, please visit the website at http://www.viropharma.com |